Cassava Sciences, Inc. (SAVA)
After hours:
| Previous close | 30.92 |
| Open | 30.50 |
| Bid | 29.57 x 1000 |
| Ask | 29.81 x 1000 |
| Day's range | 29.40 - 30.90 |
| 52-week range | 13.84 - 62.49 |
| Volume | |
| Avg. volume | 1,580,355 |
| Market cap | 1.235B |
| Beta (5Y monthly) | -0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | 84.00 |
- Motley Fool
3 Big Reasons to Sell Cassava Sciences Stock Right Now
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.
- GlobeNewswire
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point
- Zacks
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
